Please use a PC Browser to access Register-Tadawul
Get It
Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study
Johnson & Johnson JNJ | 239.63 | -2.31% |
